Glomerulonephritis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Glomerulonephritis – Pipeline Review, H2 2019’, provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis

– The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects

– The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Glomerulonephritis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Achillion Pharmaceuticals Inc

Aduro BioTech Inc

Alexion Pharmaceuticals Inc

Algomedix Inc

Alnylam Pharmaceuticals Inc

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp

Apellis Pharmaceuticals Inc

Aravive Inc

Aurinia Pharmaceuticals Inc

Biogen Inc

Bristol-Myers Squibb Co

Calliditas Therapeutics AB

Cellmid Ltd

Certa Therapeutics Pty Ltd

ChemoCentryx Inc

Coegin Pharma AS

Complexa Inc

Cytodesign Inc

Dimerix Bioscience Pty Ltd

Ergon Pharmaceuticals LLC

Goldfinch Biopharma Inc

HanAll Biopharma Co Ltd

Ionis Pharmaceuticals Inc

Kyowa Kirin Co Ltd

Merck KGaA

MorphoSys AG

Novartis AG

NovelMed Therapeutics Inc

Omeros Corp

Oraxion Therapeutics Inc

Pfizer Inc

Polyneuron Pharmaceuticals AG

Ra Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Retrophin Inc

Sarfez Pharmaceuticals Inc

Sujana Biotech, LLC

Takeda Pharmaceutical Co Ltd

Vertex Pharmaceuticals Inc

Visterra Inc

ZyVersa Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Glomerulonephritis Overview 6

Glomerulonephritis Therapeutics Development 7

Glomerulonephritis Therapeutics Assessment 16

Glomerulonephritis Companies Involved in Therapeutics Development 25

Glomerulonephritis Drug Profiles 41

Glomerulonephritis Dormant Projects 195

Glomerulonephritis Discontinued Products 197

Glomerulonephritis Product Development Milestones 198

Appendix 206

List of Tables

“List of Tables

Number of Products under Development for Glomerulonephritis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Glomerulonephritis – Pipeline by Achillion Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Aduro BioTech Inc, H2 2019

Glomerulonephritis – Pipeline by Alexion Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Algomedix Inc, H2 2019

Glomerulonephritis – Pipeline by Alnylam Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Amyndas Pharmaceuticals LLC, H2 2019

Glomerulonephritis – Pipeline by Angion Biomedica Corp, H2 2019

Glomerulonephritis – Pipeline by Apellis Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Aravive Inc, H2 2019

Glomerulonephritis – Pipeline by Aurinia Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Biogen Inc, H2 2019

Glomerulonephritis – Pipeline by Bristol-Myers Squibb Co, H2 2019

Glomerulonephritis – Pipeline by Calliditas Therapeutics AB, H2 2019

Glomerulonephritis – Pipeline by Cellmid Ltd, H2 2019

Glomerulonephritis – Pipeline by Certa Therapeutics Pty Ltd, H2 2019

Glomerulonephritis – Pipeline by ChemoCentryx Inc, H2 2019

Glomerulonephritis – Pipeline by Coegin Pharma AS, H2 2019

Glomerulonephritis – Pipeline by Complexa Inc, H2 2019

Glomerulonephritis – Pipeline by Cytodesign Inc, H2 2019

Glomerulonephritis – Pipeline by Dimerix Bioscience Pty Ltd, H2 2019

Glomerulonephritis – Pipeline by Ergon Pharmaceuticals LLC, H2 2019

Glomerulonephritis – Pipeline by Goldfinch Biopharma Inc, H2 2019

Glomerulonephritis – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Glomerulonephritis – Pipeline by Ionis Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Kyowa Kirin Co Ltd, H2 2019

Glomerulonephritis – Pipeline by Merck KGaA, H2 2019

Glomerulonephritis – Pipeline by MorphoSys AG, H2 2019

Glomerulonephritis – Pipeline by Novartis AG, H2 2019

Glomerulonephritis – Pipeline by NovelMed Therapeutics Inc, H2 2019

Glomerulonephritis – Pipeline by Omeros Corp, H2 2019

Glomerulonephritis – Pipeline by Oraxion Therapeutics Inc, H2 2019

Glomerulonephritis – Pipeline by Pfizer Inc, H2 2019

Glomerulonephritis – Pipeline by Polyneuron Pharmaceuticals AG, H2 2019

Glomerulonephritis – Pipeline by Ra Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Reata Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Retrophin Inc, H2 2019

Glomerulonephritis – Pipeline by Sarfez Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Sujana Biotech, LLC, H2 2019

Glomerulonephritis – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Glomerulonephritis – Pipeline by Vertex Pharmaceuticals Inc, H2 2019

Glomerulonephritis – Pipeline by Visterra Inc, H2 2019

Glomerulonephritis – Pipeline by ZyVersa Therapeutics Inc, H2 2019

Glomerulonephritis – Dormant Projects, H2 2019

Glomerulonephritis – Dormant Projects, H2 2019 (Contd..1), H2 2019

Glomerulonephritis – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Glomerulonephritis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports